1. Home
  2. SHO vs LQDA Comparison

SHO vs LQDA Comparison

Compare SHO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHO
  • LQDA
  • Stock Information
  • Founded
  • SHO 1995
  • LQDA 2004
  • Country
  • SHO United States
  • LQDA United States
  • Employees
  • SHO N/A
  • LQDA N/A
  • Industry
  • SHO Hotels/Resorts
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHO Consumer Discretionary
  • LQDA Health Care
  • Exchange
  • SHO Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • SHO 1.7B
  • LQDA 1.7B
  • IPO Year
  • SHO 1995
  • LQDA 2018
  • Fundamental
  • Price
  • SHO $9.57
  • LQDA $27.89
  • Analyst Decision
  • SHO Hold
  • LQDA Strong Buy
  • Analyst Count
  • SHO 7
  • LQDA 10
  • Target Price
  • SHO $9.36
  • LQDA $31.40
  • AVG Volume (30 Days)
  • SHO 2.4M
  • LQDA 3.1M
  • Earning Date
  • SHO 08-06-2025
  • LQDA 08-12-2025
  • Dividend Yield
  • SHO 3.77%
  • LQDA N/A
  • EPS Growth
  • SHO N/A
  • LQDA N/A
  • EPS
  • SHO 0.02
  • LQDA N/A
  • Revenue
  • SHO $934,999,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • SHO $6.65
  • LQDA $362.31
  • Revenue Next Year
  • SHO $3.72
  • LQDA $418.29
  • P/E Ratio
  • SHO $503.26
  • LQDA N/A
  • Revenue Growth
  • SHO 0.37
  • LQDA 30.20
  • 52 Week Low
  • SHO $7.45
  • LQDA $8.75
  • 52 Week High
  • SHO $12.41
  • LQDA $28.82
  • Technical
  • Relative Strength Index (RSI)
  • SHO 63.75
  • LQDA 74.40
  • Support Level
  • SHO $9.23
  • LQDA $26.06
  • Resistance Level
  • SHO $9.59
  • LQDA $28.82
  • Average True Range (ATR)
  • SHO 0.22
  • LQDA 1.44
  • MACD
  • SHO 0.06
  • LQDA 0.03
  • Stochastic Oscillator
  • SHO 97.96
  • LQDA 89.58

About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: